Anti-cancer DC Cell Vaccination to Treat Solid Tumors

Recruiting now · Phase 1

Conditions studied: Solid Tumor, Adult, DC

In brief

Placental or tumor-derived heat shock protein gp96 is collected, purified, and stored. The DC cells are isolated from the patient's blood and then cocultured with the gp96 to obtain the activated DC cell product. The manufactured DC cells are subcutaneously or intra-tumor injected into the patient. Clinical studies will be performed to test anti-cancer function of the DC vaccination for immunotherapy of cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the DC vaccine immunotherapy on advanced cancers will firstly be evaluated.

Key facts

Study ID
NCT06477614
Run by
Second Affiliated Hospital of Guangzhou Medical University
People needed
60
Starts
2024-06-05
Expected to finish
2035-12-30
Last updated by the study team
2024-06-27

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.